Data from network meta-analyses can inform clinical practice guidelines and decision-making in diabetes management: perspectives of the taskforce of the guideline workshop

Antonio Ceriello; Helena W. Rodbard; Tadej Battelino; Frank Brosius; Francesco Cosentino; Jennifer Green; Linong Ji; Monika Kellerer; Susan Koob; Mikhail Kosiborod; Nebojsa Lalic; Nikolaus Marx; T. Prashant Nedungadi; Christopher G. Parkin; Lars Rydén; Wayne Huey Herng Sheu; Eberhard Standl; Per Olav Vandvik; Oliver Schnell

doi:10.1186/s12933-023-01993-3

Data from network meta-analyses can inform clinical practice guidelines and decision-making in diabetes management: perspectives of the taskforce of the guideline workshop

Antonio Ceriello, Helena W. Rodbard, Tadej Battelino, Frank Brosius, Francesco Cosentino, Jennifer Green, Linong Ji, Monika Kellerer, Susan Koob, Mikhail Kosiborod, Nebojsa Lalic, Nikolaus Marx, T. Prashant Nedungadi, Christopher G. Parkin, Lars Rydén, Wayne Huey Herng Sheu, Eberhard Standl, Per Olav Vandvik, Oliver Schnell

Research output: Contribution to journal › Comment/debate › peer-review

4 Scopus citations

Abstract

In recent years, several novel agents have become available to treat individuals with type 2 diabetes (T2D), such as sodium-glucose cotransporter-2 inhibitors (SGLT-2i), tirzepatide, which is a dual glucose-dependent insulinotropic polypeptide receptor agonist (GIP RA)/glucagon-like peptide-1 receptor agonist (GLP-1 RA), and finerenone, a non-steroidal mineralocorticoid receptor antagonist (MRA) that confers significant renal and cardiovascular benefits in individuals with (CKD). New medications have the potential to improve the lives of individuals with diabetes. However, clinicians are challenged to understand the benefits and potential risks associated with these new and emerging treatment options. In this article, we discuss how use of network meta-analyses (NMA) can fill this need.

Original language	English (US)
Article number	277
Journal	Cardiovascular Diabetology
Volume	22
Issue number	1
DOIs	https://doi.org/10.1186/s12933-023-01993-3
State	Published - Dec 2023
Externally published	Yes

Keywords

(GIP RA)
Finerenone
Glucagon-like peptide-1 receptor agonist (GLP-1 RA)
Glucose-dependent insulinotropic polypeptide
Network meta-analysis
Randomized controlled trial
Sodium glucose cotransporter 2 inhibitor
Tirzepatide

ASJC Scopus subject areas

Internal Medicine
Endocrinology, Diabetes and Metabolism
Cardiology and Cardiovascular Medicine

Access to Document

10.1186/s12933-023-01993-3

Cite this

Ceriello, A., Rodbard, H. W., Battelino, T., Brosius, F., Cosentino, F., Green, J., Ji, L., Kellerer, M., Koob, S., Kosiborod, M., Lalic, N., Marx, N., Nedungadi, T. P., Parkin, C. G., Rydén, L., Sheu, W. H. H., Standl, E., Vandvik, P. O., & Schnell, O. (2023). Data from network meta-analyses can inform clinical practice guidelines and decision-making in diabetes management: perspectives of the taskforce of the guideline workshop. Cardiovascular Diabetology, 22(1), Article 277. https://doi.org/10.1186/s12933-023-01993-3

Data from network meta-analyses can inform clinical practice guidelines and decision-making in diabetes management: perspectives of the taskforce of the guideline workshop. / Ceriello, Antonio; Rodbard, Helena W.; Battelino, Tadej et al.
In: Cardiovascular Diabetology, Vol. 22, No. 1, 277, 12.2023.

Research output: Contribution to journal › Comment/debate › peer-review

Ceriello, A, Rodbard, HW, Battelino, T, Brosius, F, Cosentino, F, Green, J, Ji, L, Kellerer, M, Koob, S, Kosiborod, M, Lalic, N, Marx, N, Nedungadi, TP, Parkin, CG, Rydén, L, Sheu, WHH, Standl, E, Vandvik, PO & Schnell, O 2023, 'Data from network meta-analyses can inform clinical practice guidelines and decision-making in diabetes management: perspectives of the taskforce of the guideline workshop', Cardiovascular Diabetology, vol. 22, no. 1, 277. https://doi.org/10.1186/s12933-023-01993-3

@article{4afa1146b2fc430c91b28a9cb5d36780,

title = "Data from network meta-analyses can inform clinical practice guidelines and decision-making in diabetes management: perspectives of the taskforce of the guideline workshop",

abstract = "In recent years, several novel agents have become available to treat individuals with type 2 diabetes (T2D), such as sodium-glucose cotransporter-2 inhibitors (SGLT-2i), tirzepatide, which is a dual glucose-dependent insulinotropic polypeptide receptor agonist (GIP RA)/glucagon-like peptide-1 receptor agonist (GLP-1 RA), and finerenone, a non-steroidal mineralocorticoid receptor antagonist (MRA) that confers significant renal and cardiovascular benefits in individuals with (CKD). New medications have the potential to improve the lives of individuals with diabetes. However, clinicians are challenged to understand the benefits and potential risks associated with these new and emerging treatment options. In this article, we discuss how use of network meta-analyses (NMA) can fill this need.",

keywords = "(GIP RA), Finerenone, Glucagon-like peptide-1 receptor agonist (GLP-1 RA), Glucose-dependent insulinotropic polypeptide, Network meta-analysis, Randomized controlled trial, Sodium glucose cotransporter 2 inhibitor, Tirzepatide",

author = "Antonio Ceriello and Rodbard, {Helena W.} and Tadej Battelino and Frank Brosius and Francesco Cosentino and Jennifer Green and Linong Ji and Monika Kellerer and Susan Koob and Mikhail Kosiborod and Nebojsa Lalic and Nikolaus Marx and Nedungadi, {T. Prashant} and Parkin, {Christopher G.} and Lars Ryd{\'e}n and Sheu, {Wayne Huey Herng} and Eberhard Standl and Vandvik, {Per Olav} and Oliver Schnell",

note = "Publisher Copyright: {\textcopyright} 2023, BioMed Central Ltd., part of Springer Nature.",

year = "2023",

month = dec,

doi = "10.1186/s12933-023-01993-3",

language = "English (US)",

volume = "22",

journal = "Cardiovascular Diabetology",

issn = "1475-2840",

publisher = "BioMed Central",

number = "1",

}

TY - JOUR

T1 - Data from network meta-analyses can inform clinical practice guidelines and decision-making in diabetes management

T2 - perspectives of the taskforce of the guideline workshop

AU - Ceriello, Antonio

AU - Rodbard, Helena W.

AU - Battelino, Tadej

AU - Brosius, Frank

AU - Cosentino, Francesco

AU - Green, Jennifer

AU - Ji, Linong

AU - Kellerer, Monika

AU - Koob, Susan

AU - Kosiborod, Mikhail

AU - Lalic, Nebojsa

AU - Marx, Nikolaus

AU - Nedungadi, T. Prashant

AU - Parkin, Christopher G.

AU - Rydén, Lars

AU - Sheu, Wayne Huey Herng

AU - Standl, Eberhard

AU - Vandvik, Per Olav

AU - Schnell, Oliver

PY - 2023/12

Y1 - 2023/12

N2 - In recent years, several novel agents have become available to treat individuals with type 2 diabetes (T2D), such as sodium-glucose cotransporter-2 inhibitors (SGLT-2i), tirzepatide, which is a dual glucose-dependent insulinotropic polypeptide receptor agonist (GIP RA)/glucagon-like peptide-1 receptor agonist (GLP-1 RA), and finerenone, a non-steroidal mineralocorticoid receptor antagonist (MRA) that confers significant renal and cardiovascular benefits in individuals with (CKD). New medications have the potential to improve the lives of individuals with diabetes. However, clinicians are challenged to understand the benefits and potential risks associated with these new and emerging treatment options. In this article, we discuss how use of network meta-analyses (NMA) can fill this need.

AB - In recent years, several novel agents have become available to treat individuals with type 2 diabetes (T2D), such as sodium-glucose cotransporter-2 inhibitors (SGLT-2i), tirzepatide, which is a dual glucose-dependent insulinotropic polypeptide receptor agonist (GIP RA)/glucagon-like peptide-1 receptor agonist (GLP-1 RA), and finerenone, a non-steroidal mineralocorticoid receptor antagonist (MRA) that confers significant renal and cardiovascular benefits in individuals with (CKD). New medications have the potential to improve the lives of individuals with diabetes. However, clinicians are challenged to understand the benefits and potential risks associated with these new and emerging treatment options. In this article, we discuss how use of network meta-analyses (NMA) can fill this need.

KW - (GIP RA)

KW - Finerenone

KW - Glucagon-like peptide-1 receptor agonist (GLP-1 RA)

KW - Glucose-dependent insulinotropic polypeptide

KW - Network meta-analysis

KW - Randomized controlled trial

KW - Sodium glucose cotransporter 2 inhibitor

KW - Tirzepatide

UR - http://www.scopus.com/inward/record.url?scp=85174272130&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85174272130&partnerID=8YFLogxK

U2 - 10.1186/s12933-023-01993-3

DO - 10.1186/s12933-023-01993-3

M3 - Comment/debate

C2 - 37833776

AN - SCOPUS:85174272130

SN - 1475-2840

VL - 22

JO - Cardiovascular Diabetology

JF - Cardiovascular Diabetology

IS - 1

M1 - 277

ER -

Data from network meta-analyses can inform clinical practice guidelines and decision-making in diabetes management: perspectives of the taskforce of the guideline workshop

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this